Consolidated Year 31/12/2020 2020 Company Q2 30/06/2020 2020 Consolidated Q2 30/06/2020 2019 Reviewed Company Q3 30/09/2019 Unable to reach any conclusion with an emphasis of matters
by its indirect subsidiary Indorama Netherlands B.V. (“INBV”) of 83,000,000 newly issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged
2020 Reviewed Company Q2 30/06/2020 Unable to reach any conclusion with an emphasis of matters /Others 2020 Reviewed Consolidated Q2 30/06/2020 Unable to reach any conclusion with an emphasis of
Reviewed Company Q3 30/09/2019 Unable to reach any conclusion with an emphasis of matters 2019 Reviewed Consolidated Q3 30/09/2019 Unable to reach any conclusion with an emphasis of matters 2019 Reviewed
Statement MD&A Financial Statement Revise 2020 Reviewed Company Q2 30/06/2020 Unable to reach any conclusion with an emphasis of matters /Others 2020 Reviewed Consolidated Q2 30/06/2020 Unable to reach
Statement MD&A Financial Statement Revise 2020 Reviewed Company Q3 30/09/2020 2020 Reviewed Consolidated Q3 30/09/2020 2020 Reviewed Company Q2 30/06/2020 Unable to reach any conclusion with an
opinion with an emphasis of matters 2019 Reviewed Company Q3 30/09/2019 Unable to reach any conclusion with an emphasis of matters 2019 Reviewed Consolidated Q3 30/09/2019 Unable to reach any conclusion
or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In